Feedback / Questions
AMT-253 ADC - Multitude Therap
https://www.prnewswire.com/news-releases/multitude-therapeutics-announces-encouraging-interim-phase-iii-results-from-ongoing-first-in-human-study-evaluating-its-muc18-directed-antibody-drug-conjugate-amt-253-in-melanoma-and-other-advanced-solid-tumors-at-the-2025-esmo-302588336.html
Oct 19, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next